New treatments for chronic hepatitis C infection

The goal of HCV treatment is to prevent cirrhosis, hepatocellularcarcinoma, liver-related deaths. The development of direct-actingantiviral (DAA) agents which target various steps in HCV lifecycleled to a revolution by providing nearly complete eradication ofHCV. The new treatment regimens with high cure rates havechanged the standards of care in the regions where patients haveaccess to new treatments. This review addresses the recent updatesin management of chronic hepatitis C infection.Keywords: Hepatitis C, New treatments, Direct antiviral agents

Anahtar Kelimeler:

Hepatit C, Yeni tedaviler, Direkt antiviral ajanlar

New treatments for chronic hepatitis C infection

PDF

___

Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon
alfa-2b plus ribavirin compared with interferon alfa-2b
plus ribavirin for initial treatment of chronic hepatitis C: a
randomised trial. Lancet 2001;358:958-65.
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon
alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med 2002;47:975-82.
Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferonalpha2a
and ribavirin combination therapy in chronic hepatitis
C: a randomized study of treatment duration and ribavirin
dose. Ann Intern Med 2004;140:346-55.
Bacon BR, Gordon SC, Lawitz E, et al.
Boceprevir for previously treated chronic HCV genotype 1
infection. N Engl J
Med 2011;364:1207–17.
Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir
for previously untreated chronic hepatitis C virus infection. N
Engl J Med 2011;364:2405-16.
Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for
untreated chronic HCV genotype 1 infection. N Engl J Med
364:1195-206.
Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment
of HCV infection. N Engl J Med 2011;364:2417-28.
EASL Recommendations on Treatment of Hepatitis C 2015.
J Hepatol 2015;63:199-236.
AASLD/IDSA/IAS-USA. Recommendations for testing
managing, and treating hepatitis C. [Accessed on October
.Available from: URL: http://www.hcvguidelines.org
Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C
virus genotypes 4, 5, and 6: an international consensus report.
Liver Int 2010;30:342-55.
Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir
plus sofosbuvir, with or without ribavirin, to treat chronic
infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive
patients: the COSMOS randomised study. Lancet 2014
1756-65.
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously
untreated chronic hepatitis C 79. infection. N Engl J Med
368:1878-87.
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir
for hepatitis C genotype 2 or 3 in patients without treatment
options. N Engl J Med 2013; 368:1867-77.
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and
sofosbuvir for previously treated HCV genotype 1 infection.
N Engl J Med 2014;370:1483-93.
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir
for untreated HCV genotype 1 infection. N Engl J Med 2014
1889-98.
Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir
and sofosbuvir for 8 or 12 weeks for chronic HCV without
cirrhosis. N Engl J Med 2014;370:1879-88.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al.
Daclatasvir plus sofosbuvir for previously treated or untreated
chronic HCV infection. N Engl J Med 2014;370:211–21.
Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus
Sofosbuvir for HCV in patients coinected with HIV-1. N Eng
J Med 2015;373:714-25.
Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR
Crawford D. Treatment of HCV with ABT-450/rombitasvir
and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-
Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV
with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N
Engl J Med 2014;370:1604-14.
Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci
P, Maieron A. ABT-450, ritonavir, ombitasvir, and dasabuvir
achieves 97% and 100% sustained virologic response with or
without ribavirin in treatmentexperienced patients with HCV
genotype 1b infection. Gastroenterology 2014; 147:359-365.
e1.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper
C. ABT-450/r-ombitasvir and dasabuvir with or without
ribavirin for HCV. N Engl J Med 2014; 370:1983-92.
Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir
and dasabuvir with ribavirin for hepatitis C with cirrhosis. N
Engl J Med 2014;370:1973-82.
Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised
open-label study to evaluate the efficacy and safety of 8 and
weeks of simeprevir (SMV) plus sofosbuvir (SOF) in
treatment-naive and –experienced patients with chronic HCV
genotype 1 infection without cirrhosis: Optimist-1. J Hepatol
62 (Suppl 2): S270.
Lawitz E, Matusow G, DeJesus E, et al. A phase 3, open
label, single-arm study to evaluate the efficacy and safety
of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in
treatment-naive or –experienced patients with chronic HCV
genotype 1 infection and cirrhosis: Optimist-2. J Hepatol
62 (Suppl 2): S264-265.
Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis
The outcome of antiviral therapy in HCV genotype 2 and
genotype 3 infected patients with chronic hepatitis. Aliment
Pharmacol Ther 2008; 28: 397-404.
Nelson DR, Cooper JN, Lalezari JP, et al, for the ALLY-3
Study Team. All-oral 12-week treatment with daclatasvir
plus sofosbuvir in patients with hepatitis C virus genotype
infection: ALLY-3 phase III study. Hepatology
61:1127-35.
Hezode C, De Ledinghen V, Fonatine H, et al. Daclatasvir
plus sofosbuvir with or without ribavirin in patients with
HCV genotype 3 infection: Interim analysis of a French
multicenter compassionate program. J Hepatol 2015; 62
(Suppl 2): S265-266.
Mohamoud YA, Mumtaz GR, Riome S, et al. The
epidemiology of hepatitis C virus in Egypt: a systematic
review and data synthesis. BMC Infect Dis 2013;13:1-21.